HR+ HER2- Breast Cancer

Welcome to the HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA,

UCHealth Memorial Hospital

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

HR+ HER2- Breast Cancer Resource Center

Interview with Christina Lew, PharmD, BCPS: Research Highlights from the 2024 San Antonio Breast Cancer Symposium on Early-Stage Disease

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Intravenous Cancer Treatment Education

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Clinical Management of Patients Taking Abemaciclib

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Nature Communications

Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Drugs

Efficacy and safety of CDK4/6 inhibitors: A focus on HR+/HER2- early breast cancer

Journal of Clinical Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

U.S. Food and Drug Administration

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: The first case report for combination efficacy and safety

The Journal of Pathology. Clinical Research

High chromosomal instability is associated with higher 10-year risks of recurrence for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Clinical evidence from a large-scale, multiple-site, retrospective study

Clinical Breast Cancer

Real world evidence study to assess incidence, treatment patterns, clinical outcomes, and health care resource utilization in early-stage, high-risk HER2-negative breast cancer in Alberta, Canada

Oncology Research and Treatment

Palbociclib in combination with either aromatase inhibitors or fulvestrant for patients with advanced HR+/HER2- breast cancer in Germany: Final results of the phase 2 multicohort INGE-B trial

Therapeutic Advances in Medical Oncology

Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: A multicenter real-world study

Cureus

Dormancy leading to late recurrence in breast cancer: A case of hormone receptor-positive supraclavicular metastasis 10 years after the initial treatment

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer